Yarandi N, Shirali AC (2023) Onco-nephrology: kidney disease in a cancer patient. Med Clin North Am 107:749–762. https://doi.org/10.1016/j.mcna.2023.03.007

Article  PubMed  Google Scholar 

Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Cruz FM, Wyrwicz L, Stroyakovskiy D, Pápai Z et al (2023) Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med 388:1657–1667. https://doi.org/10.1056/NEJMoa2214963

Article  CAS  PubMed  Google Scholar 

Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621–630. https://doi.org/10.1056/NEJMoa1406470

Article  CAS  PubMed  Google Scholar 

Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K et al (2015) Cabozantinib versus everolimus in advanced Renal-Cell carcinoma. N Engl J Med 373:1814–1823. https://doi.org/10.1056/NEJMoa1510016

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cosmai L, Gallieni MC et al (2017) Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). J Nephrol 30:171–180. https://doi.org/10.1007/s40620-016-0311-8

Article  CAS  PubMed  Google Scholar 

Apte RS, Chen DS, Ferrara N (2019) VEGF in signaling and disease: beyond discovery and development. Cell 176:1248–1264. https://doi.org/10.1016/j.cell.2019.01.021

Article  CAS  PubMed  PubMed Central  Google Scholar 

Elebiyo TC, Rotimi D, Evbuomwan IO, Maimako RF, Iyobhebhe M, Ojo OA, Oluba OM, Adeyemi OS (2022) Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy. Cancer Treat Res Commun 32:100620. https://doi.org/10.1016/j.ctarc.2022.100620

Article  PubMed  Google Scholar 

Van Wynsberghe M, Flejeo J, Sakhi H, Ollero M, Sahali D, Izzedine H, Henique C (2021) Nephrotoxicity of anti-angiogenic therapies. Diagnostics (Basel) 11:640. https://doi.org/10.3390/diagnostics11040640

Article  CAS  PubMed  Google Scholar 

Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I et al (2022) Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 386:437–448. https://doi.org/10.1056/NEJMoa2108330

Article  CAS  PubMed  PubMed Central  Google Scholar 

Enokida T, Tahara M (2021) Management of VEGFR-targeted TKI for thyroid cancer. Cancers (Basel) 13:5536. https://doi.org/10.3390/cancers13215536

Article  CAS  PubMed  Google Scholar 

Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16:499–508. https://doi.org/10.1016/S1470-2045(15)70127-0

Article  CAS  PubMed  Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894–1905. https://doi.org/10.1056/NEJMoa1915745

Article  CAS  PubMed  Google Scholar 

Selby NM, Taal MW (2020) An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab 22 Suppl 1:3–15. https://doi.org/10.1111/dom.14007

Article  Google Scholar 

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A Collaborators developing the Japanese equation for estimated GFR (2009) revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992. https://doi.org/10.1053/j.ajkd.2008.12.034

Iwasaki H, Yamazaki H, Takasaki H, Suganuma N, Sakai R, Nakayama H, Toda S, Masudo K (2019) Renal dysfunction in patients with radioactive iodine-refractory thyroid cancer treated with tyrosine kinase inhibitors: A retrospective study. Med (Baltim) 98:e17588. https://doi.org/10.1097/MD.0000000000017588

Article  CAS  Google Scholar 

Masaki C, Sugino K, Kobayashi S, Hosoi Y, Ono R, Yamazaki H, Akaishi J, Hames KY, Tomoda C, Suzuki A et al (2021) Impact of lenvatinib on renal function: Long-term analysis of differentiated thyroid cancer patients. BMC Cancer 21:894. https://doi.org/10.1186/s12885-021-08622-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shibutani Y, Suzuki S, Sagara A, Enokida T, Okano S, Fujisawa T, Sato F, Yumoto T, Sano M, Kawasaki T, Tahara M (2023) Impact of lenvatinib-induced proteinuria and renal dysfunction in patients with thyroid cancer. Front Oncol 13:1154771. https://doi.org/10.3389/fonc.2023.1154771

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muramatsu T, Takahashi M, Kakinuma R, Sato T, Yamamoto M, Akazawa M, Tanaka K, Kikuchi T, Kushiyama A (2022) Decline in renal function associated with cardiovascular autonomic neuropathy positively coordinated with proteinuria in patients with type 2 diabetes. J Diabetes Investig 13:102–111. https://doi.org/10.1111/jdi.13625

Article  CAS  PubMed  Google Scholar 

Estrada CC, Maldonado A, Mallipattu SK (2019) Therapeutic Inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol 30:187–200. https://doi.org/10.1681/ASN.2018080853

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oshima M, Shimizu M, Yamanouchi M, Toyama T, Hara A, Furuichi K, Wada T (2021) Trajectories of kidney function in diabetes: A clinicopathological update. Nat Rev Nephrol 17:740–750. https://doi.org/10.1038/s41581-021-00462-y

Article  PubMed  Google Scholar 

Kataoka S, Nishikawa Y, Funakoshi T, Horimatsu T, Sakuragi M, Uchino E, Hiragi S, Yamamoto S, Sakai K, Matsubara T et al (2024) Proteinuria frequency and subsequent renal dysfunction in bevacizumab-treated patients: A single center, retrospective, observational study. Int J Clin Oncol 29:398–406. https://doi.org/10.1007/s10147-024-02474-7

Article  CAS  PubMed  Google Scholar 

Fujii T, Kawasoe K, Tonooka A, Ohta A, Nitta K (2019) Nephrotic syndrome associated with ramucirumab therapy: A single-center case series and literature review. Med (Baltim) 98:e16236. https://doi.org/10.1097/MD.0000000000016236

Article  CAS  Google Scholar 

Uy AL, Simper NB, Champeaux AL, Perkins RM (2009) Progressive bevacizumab-associated renal thrombotic microangiopathy. NDT Plus 2:36–39. https://doi.org/10.1093/ndtplus/sfn168

Article  CAS  PubMed  Google Scholar